Reduced expression of SATB2 has been associated with poor prognosis in colorectal adenocarcinoma, while in head and neck squamous carcinoma, the loss of SATB2 expression was associated with recurrence and high tumor grade [55]. This evidence concerns the gene SATB2 and colorectal adenocarcinoma.